Skip to Main Content

Author Details

Cristina Rodr??guez-Antona
Spanish National Cancer Research Center (CNIO)
2000
195
49
PMIDPaper TitleJournal TitlePublished Year
36572991CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.Cancer2023
36993533Tumour mitochondrial DNA mutations drive aerobic glycolysis to enhance checkpoint blockade.bioRxiv2023
37448346Radiation therapy for low- and high-risk perineural invasion in head and neck cutaneous squamous cell carcinoma: Clinical outcomes and patterns of failure.Head Neck2023
37369443Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis.Can J Surg2023
37139660DLST mutations in pheochromocytoma and paraganglioma cause proteome hyposuccinylation and metabolic remodeling.Cancer Commun (Lond)2023
37293154<i>PBRM1</i> and <i>KDM5C</i> cooperate to define high-angiogenesis tumors and increased antiangiogenic response in renal cancer.Am J Cancer Res2023
37260183Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition.Int J Cancer2023
36854674Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma.Nat Commun2023
34032273Clinical Pharmacogenetics Implementation Consortium Guideline for the Use of Aminoglycosides Based on MT-RNR1 Genotype.Clin Pharmacol Ther2022
35847482Cabozantinib for the treatment of solid tumors: a systematic review.Ther Adv Med Oncol2022
35740506Genome-Wide Meta-Analysis Identifies Variants in <i>DSCAM</i> and <i>PDLIM3</i> That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib.Cancers (Basel)2022
35349227Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients.Cancer Med2022
35434343A phase I/II trial of concurrent immunotherapy with chemoradiation in locally advanced larynx cancer.Laryngoscope Investig Otolaryngol2022
35688666Interrogating the Significance of PARP1 Expression and PBRM1 Mutation as Biomarkers for Predicting the Response to Atezolizumab plus Bevacizumab or to Sunitinib in Patients with Clear Cell Renal Cell Carcinoma.Eur Urol2022
35923927Cabozantinib combination therapy for the treatment of solid tumors: a systematic review.Ther Adv Med Oncol2022
36053203Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.J Natl Cancer Inst2022
35979662Comprehensive molecular analysis of immortalization hallmarks in thyroid cancer reveals new prognostic markers.Clin Transl Med2022
35880554Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel.Pharmacogenomics2022
35181665Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data.NPJ Genom Med2022
35276673NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022.J Natl Compr Canc Netw2022
35202484PharmVar GeneFocus: CYP3A5.Clin Pharmacol Ther2022
34847733High End-of-Life Health Care Utilization in a Contemporary Cohort of Head and Neck Cancer Patients Treated with Immune Checkpoint Inhibitors.J Palliat Med2022
33442023Prevalence of pathogenic germline variants in patients with metastatic renal cell carcinoma.Genet Med2021
33800656MicroRNAs Possibly Involved in the Development of Bone Metastasis in Clear-Cell Renal Cell Carcinoma.Cancers (Basel)2021
34638246Analysis of Telomere Maintenance Related Genes Reveals <i>NOP10</i> as a New Metastatic-Risk Marker in Pheochromocytoma/Paraganglioma.Cancers (Basel)2021
34205829MicroRNAs Targeting HIF-2α, VEGFR1 and/or VEGFR2 as Potential Predictive Biomarkers for VEGFR Tyrosine Kinase and HIF-2α Inhibitors in Metastatic Clear-Cell Renal Cell Carcinoma.Cancers (Basel)2021
34200459Circulating Levels of the Interferon-γ-Regulated Chemokines CXCL10/CXCL11, IL-6 and HGF Predict Outcome in Metastatic Renal Cell Carcinoma Patients Treated with Antiangiogenic Therapy.Cancers (Basel)2021
34190375Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial.Oncologist2021
31335987PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.Int J Cancer2020
34704693The need of the clinical implementation of pharmacogenetics in European health services for routine drug prescription. What's next? An urgent clinical unmet need for patients.Drug Metab Pers Ther2020
32081561MicroRNAs as potential predictors of extreme response to tyrosine kinase inhibitors in renal cell cancer.Urol Oncol2020
31796519A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer.Clin Cancer Res2020
33377638Overexpression of miR-483-5p is confined to metastases and linked to high circulating levels in patients with metastatic pheochromocytoma/paraganglioma.Clin Transl Med2020
33185569The need of the clinical implementation of pharmacogenetics in European health services for routine drug prescription. What's next? An urgent clinical unmet need for patients.Drug Metab Pers Ther2020
33182397Novel <i>DNMT3A</i> Germline Variant in a Patient with Multiple Paragangliomas and Papillary Thyroid Carcinoma.Cancers (Basel)2020
32634781Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw2020
32915890MicroRNA expression profiles in molecular subtypes of clear-cell renal cell carcinoma are associated with clinical outcome and repression of specific mRNA targets.PLoS One2020
32683206Genetic association of gemcitabine/carboplatin-induced leukopenia and neutropenia in non-small cell lung cancer patients using whole-exome sequencing.Lung Cancer2020
32630724A Novel Approach for the Identification of Pharmacogenetic Variants in <i>MT-RNR1</i> through Next-Generation Sequencing Off-Target Data.J Clin Med2020
32791518CD133 Expression in Medullary Thyroid Cancer Cells Identifies Patients with Poor Prognosis.J Clin Endocrinol Metab2020
32616874Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome.Mod Pathol2020
32555365Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.Br J Cancer2020
32554541Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).Clin Cancer Res2020
32331352Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates.Biomedicines2020
32275773P-Glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Patients With Cancer.Clin Pharmacol Ther2020
31616045Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia.Pharmacogenomics J2020
31403184Hsa-miR-139-5p is a prognostic thyroid cancer marker involved in HNRNPF-mediated alternative splicing.Int J Cancer2020
30470691Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy.Oncologist2019
31861590Prognostic and Predictive Value of <i>PBRM1</i> in Clear Cell Renal Cell Carcinoma.Cancers (Basel)2019
31410193Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma.Theranostics2019
  • 1 - 50 of 195

Recommended Authors

David C Qian
Winship Cancer Institute of Emory University
Career Start Year 2015
Number of shared co-authors 14
Marzia Del Re
University of Pisa
Career Start Year 2010
Number of shared co-authors 1
Bo Gao
Crown Princess Mary Cancer Centre, Westmead Hospital
Career Start Year 2008
Number of shared co-authors 137
Gabriele Zoppoli
University of Genoa and Ospedale Policlinico San Martino
Career Start Year 2008
Number of shared co-authors 2
Jordi Rodon
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 1
Rodrigo Dienstmann
Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus
Career Start Year 2006
Number of shared co-authors 3
Albrecht Stenzinger
Institute of Pathology, University Hospital Heidelberg
Career Start Year 2005
Number of shared co-authors 6
Kouros Owzar
Duke University
Career Start Year 2005
Number of shared co-authors 18
Abul Kalam Azad
University of Dhaka
Career Start Year 2004
Number of shared co-authors 0
Pavlos Msaouel
The University of Texas MD Anderson Cancer Center
Career Start Year 2004
Number of shared co-authors 2
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 3
Kim M Smits
Maastricht University Medical Center+
Career Start Year 2003
Number of shared co-authors 0
Keyue Ding
Queen's University
Career Start Year 2002
Number of shared co-authors 0
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 2
Zhuo Chen
The First Hospital of Lanzhou University
Career Start Year 2002
Number of shared co-authors 0
Pingfu Fu
Case Western Reserve University
Career Start Year 2000
Number of shared co-authors 9
Martijn P Lolkema
Erasmus MC Cancer Institute
Career Start Year 1999
Number of shared co-authors 3
David Neil Hayes
Center for Cancer Research, University of Tennessee Health Science Center
Career Start Year 1999
Number of shared co-authors 14
Liewei Wang
Mayo Clinic
Career Start Year 1999
Number of shared co-authors 13
Anthony J Iafrate
Massachusetts General Hospital
Career Start Year 1997
Number of shared co-authors 3
Lillian L Siu
Princess Margaret Cancer Centre, University Ave
Career Start Year 1995
Number of shared co-authors 6
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 3
Sudhir Varma
Center for Cancer Research, National Cancer Institute
Career Start Year 1994
Number of shared co-authors 1
Geoffrey Liu
The Princess Margaret Cancer Centre/University of Toronto
Career Start Year 1992
Number of shared co-authors 52
Wei Xu
Princess Margaret Cancer Centre
Career Start Year 1991
Number of shared co-authors 5
Joan Albanell
Hospital del Mar Research Institute
Career Start Year 1990
Number of shared co-authors 3
Luigi Marchionni
Weill-Cornell School of Medicine
Career Start Year 1989
Number of shared co-authors 4
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 3
Mark J Ratain
University of Chicago
Career Start Year 1985
Number of shared co-authors 9
Howard L McLeod
Center for Precision Medicine and Functional Genomics, Utah Tech University
Career Start Year 1979
Number of shared co-authors 19

Collaborators

Jes??s Garc??a-Donas
HM Hospitales-Centro Integral Oncologico Clara Campal
Co-authored papers 33
Aguirre A de Cubas
Co-authored papers 14
Javier Ben??tez
Instituto de Salud Carlos III
Co-authored papers 11
Ana Osorio
Familial Cancer Clinical Unit, Spanish National Cancer Research Centre
Co-authored papers 7
Lambertus A Kiemeney
Co-authored papers 6
Robert I Haddad
Dana-Farber Cancer Institute, Harvard Medical School
Co-authored papers 6
Anne-Paule Gimenez-Roqueplo
Co-authored papers 6
Osvaldo Gra??a
Spanish National Cancer Research Centre-CNIO
Co-authored papers 6
Antonio Jimeno
University of Colorado School of Medicine
Co-authored papers 6
David G Pfister
Memorial Sloan Kettering Cancer Center
Co-authored papers 6
Anna DeFazio
Westmead Hospital
Co-authored papers 6
Anthony J Cmelak
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Co-authored papers 6
Ellen L Goode
Mayo Clinic College of Medicine
Co-authored papers 6
F??tima Al-Shahrour
Spanish National Cancer Research Centre (CNIO)
Co-authored papers 5
Lynne R Wilkens
University of Hawaii Cancer Center
Co-authored papers 5
Andrew Berchuck
Duke School of Medicine
Co-authored papers 5
Paul D P Pharoah
Center for Cancer Genetic Epidemiology, University of Cambridge
Co-authored papers 5
James D Brenton
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 5
Adrián Llerena
Co-authored papers 5
Simon A Gayther
Cedars-Sinai Medical Center
Co-authored papers 5
Susan J Ramus
School of Clinical Medicine, University of NSW Sydney, Lowy Cancer Research Centre
Co-authored papers 5
Jacek Gronwald
International Hereditary Cancer Center, Pomeranian Medical University
Co-authored papers 5
David G Huntsman
University of British Columbia
Co-authored papers 5
Mar??a J Garc??a
Spanish National Cancer Research Centre (CNIO)
Co-authored papers 5
Beth Y Karlan
David Geffen School of Medicine, University of California los angeles
Co-authored papers 5
Honglin Song
University of Cambridge
Co-authored papers 5
Peter A Fasching
Otto-Friedrich-University Bamberg
Co-authored papers 5
Marc T Goodman
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 5
Michael E Carney
John A. Burns School of Medicine, University of Hawaii
Co-authored papers 5
Susana Hernando
University Hospital Fundacion Alcorcon
Co-authored papers 5
Release 1.2